GlassScriptPhysician profile
Jonathan Arbogast
NPI 1326140906
$5,525.15
in general payments reported to CMS, 2019-2025
47 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $1,231 · 2021: $1,142 · 2022: $588 · 2023: $387 · 2024: $992 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $547.67 | 2019-2022 | |
| Abbvie INC. | $459.83 | 2019-2024 | Vraylar |
| Novo Nordisk INC | $454.63 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $447.95 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $339.59 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $310.00 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.30 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $265.81 | 2021 | |
| Lilly USA, LLC | $238.27 | 2020-2024 | Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $234.15 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $186.32 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $166.35 | 2021-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $155.16 | 2022-2024 | |
| Allergan, INC. | $135.27 | 2019-2020 | |
| Astellas Pharma US INC | $109.43 | 2019-2024 | Veozah |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Arbogast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.